PO.BCS01.06 · 生物信息与计算

IHCExplore:一个用于准确且可扩展的免疫组织化学评分的AI驱动计算病理学平台

IHCExplore: An AI-driven computational pathology platform for accurate and scalable immunohistochemistry scoring

海报缩略图:IHCExplore:一个用于准确且可扩展的免疫组织化学评分的AI驱动计算病理学平台
编号 76 展板 7 时间 4/19 02:00–05:00 区域 Section 4 主讲 Kelsey Luu
分会场 Digital Pathology 1
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Kelsey Luu1, Ciyue Shen2, Chintan Shah3, John Shamshoian3, Blake Martin1, Daniel Shenker1, Jackson nyman1, Nhat Le1, Zahil Shanis1, Syed Ashar Javed3, Matthew Bronnimann3, Robert Egger4, Harsha Pokolla1, Andrew H. Beck5, Benjamin Glass2, Jennifer Hipp3, Ryan Leung6, Jacqueline Brosnan-Cashman1, Santhosh Balasubramanian1, Bahar Rahsepar1, Emma Krause7

1PathAI, Inc., Boston, MA,2PathAI, Boston, MA,34PathAI, Inc.,5PathAI, Inc., Cambridge, MA,6Pathai, Boston, MA,7PathAI, boston, MA

摘要 Abstract

中文摘要
利用免疫组织化学(IHC)对生物标志物表达进行精确评分,影响着肿瘤学中精准治疗药物(如抗体-药物偶联物ADC)的成功。然而,病理学家的手工IHC评分受限于病理学家间和病理学家内的变异性、可扩展性差以及视觉可及(如空间)信息的局限。 IHCExplore*是一款人工智能(AI)赋能的工具,可从IHC标本中提供全面且可重复的蛋白表达表征。IHCExplore利用了病理学基础模型PLUTO,1,并在来自123种不同染色检测的24,390张全切片图像(WSI)数据集上进行了训练。该模型识别细胞类型(癌细胞和淋巴细胞),并将组织区域分割为癌上皮、癌相关基质和坏死。它进一步分割单个细胞的细胞核、细胞质和细胞膜,以在亚细胞分辨率上量化蛋白表达。 模型衍生的特征在切片层面量化表达,并将癌细胞分类为未染色、低强度、中强度和高强度类别。空间特征描述这些细胞在肿瘤微环境内的分布。其他定量读数包括连续H-score、膜:胞质强度比、表达异质性评分和空间邻近度评分(用于评估旁观者活性)。作为概念验证,IHCExplore的特征被用于按如下方式计算PD-L1肿瘤比例评分(TPSIHCExplore):膜染色高于阈值的癌细胞总数/癌细胞总数。在一个采用多种PD-L1克隆(SP263、SP142、28-8、22C3)染色的非小细胞肺癌WSI队列(N=597)中,将TPSIHCExplore与来自N=5位病理学家的手工共识TPS采用组内相关系数(ICC)进行比较。将染色阈值从预设截断值(4)调整为校准截断值(7)后,TPSIHCExplore相对于共识的ICC从0.73提高到0.91,该值与平均标注者相对于共识的ICC(0.90)相当。因此,常规IHCExplore部署的输出可通过简单的阈值优化重现现有的生物标志物评分。由此,IHCExplore是一种可扩展且准确的AI驱动的IHC评分解决方案。该模型在肿瘤类型和染色模式间泛化的能力,连同其精细的细胞区室分割,使其成为生物标志物发现、检测优化以及作为精准肿瘤学伴随诊断或评分辅助系统潜在部署的强大工具。 *IHCExplore仅供研究使用。不用于诊断程序。 1Juyal, D.等(2024)PLUTO: Pathology Universal Transformer. arXiv:2405.07905
查看英文原文 English abstract
Precise scoring of biomarker expression using immunohistochemistry (IHC) influences the success of precision therapeutics in oncology, such as antibody-drug conjugates (ADCs). However, manual IHC scoring by pathologists is limited by inter- and intra-pathologist variability, poor scalability, and limitations in visually accessible (e.g., spatial) information. IHCExplore* is an artificial intelligence (AI)-enabled tool that provides comprehensive and reproducible characterization of protein expression from an IHC specimen. IHCExplore leverages PLUTO, a pathology foundation model,1 and was trained on a dataset of 24,390 whole slide images (WSIs) from 123 distinct staining assays. The model identifies cell types (cancer cells and lymphocytes) and segments tissue regions into cancer epithelium, cancer-associated stroma, and necrosis. It further segments the nucleus, cytoplasm, and membrane of individual cells to quantify protein expression at subcellular resolution. Model-derived features quantify expression at the slide-level and classify cancer cells into unstained, low-, medium-, and high-intensity categories. Spatial features describe the distribution of these cells within the tumor microenvironment. Additional quantitative readouts include continuous H-score, membrane: cytoplasm intensity ratio, expression heterogeneity score, and spatial proximity score (to assess bystander activity).As a proof of concept, IHCExplore features were used to calculate PD-L1 tumor proportion score (TPSIHCExplore) as follows: total cancer cells with membrane staining above a threshold/total cancer cells. In a cohort of non-small cell lung cancer WSIs (N=597) stained with multiple PD-L1 clones (SP263, SP142, 28-8, 22C3), TPSIHCExplore was compared to manual consensus TPS from N=5 pathologists using intraclass correlation coefficient (ICC). After adjusting the staining threshold from a preset cutoff (4) to a calibrated cutoff (7), the ICC of TPSIHCExplore compared to consensus increased from 0.73 to 0.91, a value on par with the ICC of the average annotator compared to consensus (0.90). Therefore, outputs from routine IHCExplore deployments can recapitulate existing biomarker scoring with simple threshold optimization.Thus, IHCExplore is a scalable and accurate AI-driven solution for IHC scoring. The model's ability to generalize across tumor types and staining modalities, along with its fine-grained cell compartment segmentation, positions it as a powerful tool for biomarker discovery, assay optimization, and potential deployment as a companion diagnostic or scoring-assist system for precision oncology. *IHCExplore is For Research Use Only. Not for use in diagnostic procedures. 1Juyal, D. et al. (2024) PLUTO: Pathology Universal Transformer. arXiv:2405.07905
利益披露 Disclosure
K. Luu, PathAI Employment. C. Shen, PathAI Employment. B. Martin, pathai Employment. D. Shenker, pathai Employment. J. nyman, Pathai Employment. N. Le, PathAI Employment. Z. Shanis, PathAI Employment. H. Pokolla, PathAI Employment. B. Glass, PathAI Employment. R. Leung, pathai Employment. S. Balasubramanian, pathai Employment. B. Rahsepar, PathAI Employment. E. Krause, PathAI Employment.

← 返回 AACR 2026 检索